Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 15/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | CASP6 | P55212 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20682344 | 0.82 | TSHR (0.38) | CHRM1CHRM2GRM5 | |
| SCHEMBL11774908 | 0.80 | CHRM1 (0.43) | CHRM1CHRM5CHRM2CHRM4GRM5 | |
| SCHEMBL7850221 | 0.78 | CHRM2 (0.58) | CHRM1CHRM2JAK1 | |
| SCHEMBL20148602 | 0.77 | RAB9A (0.40) | CHRM1JAK2JAK1TYK2 | |
| SCHEMBL12128829 | 0.76 | CHRM1 (0.46) | CHRM1CHRM5CHRM2CHRM4 | |
| SCHEMBL18375130 | 0.76 | SMN1; SMN2 (0.37) | GRM5 | |
| SCHEMBL21722669 | 0.76 | HRH3 (0.33) | — | |
| SCHEMBL17354962 | 0.76 | CHRM1 (0.51) | CHRM1CHRM5CHRM4GRM5GAA | |
| SCHEMBL10063523 | 0.76 | CHRM1 (0.51) | CHRM1CHRM5CHRM4GRM5GAA | |
| SCHEMBL20008986 | 0.76 | SMN1; SMN2 (0.37) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023098832-A1 | PYRIDOPYRIMIDINE DERIVATIVES SERVING AS SMALL GTP ENZYME KRAS MUTATION INHIBITORS | 思路迪生物医药(上海)有限公司 | 2023-06-08 | — | — | WO | disclosed |
| US-7998958-B2 | Substituted N-arylsulfonylheterocyclic amines as gamma-secretase inhibitors | SCHERING CORPORATION (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998958-B2 | Substituted N-arylsulfonylheterocyclic amines as gamma-secretase inhibitors | SCHERING CORPORATION (US) | 2011-08-16 | — | — | US | disclosed |
| US-7763613-B2 | Substituted N-arylsulfonylheterocyclic amines as gamma-secretase inhibitors | SCHERING CORPORATION (US) | 2010-07-27 | — | — | US | disclosed |
| US-20100093695-A1 | Substituted N-Arylsulfonylheterocyclic Amines As Gamma-Secretase Inhibitors | SCHERING CORP. | 2010-04-15 | — | — | US | disclosed |
| US-20100093695-A1 | Substituted N-Arylsulfonylheterocyclic Amines As Gamma-Secretase Inhibitors | SCHERING CORP. | 2010-04-15 | — | — | US | disclosed |
| US-20100087425-A1 | Substituted N-Arylsulfonylheterocyclic Amines As Gamma-Secretase Inhibitors | SCHERING CORP. | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093695-A1 | Substituted N-Arylsulfonylheterocyclic Amines As Gamma-Secretase Inhibitors | BACE1, BACE2, APP | CHRM1 123/4885CHRM5 100/4885CHRM2 92/4885 |
| US-20100087425-A1 | Substituted N-Arylsulfonylheterocyclic Amines As Gamma-Secretase Inhibitors | BACE1, BACE2, APP | CHRM1 121/4885CHRM5 97/4885CHRM2 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.